TITLE:
Study of the Effect of Intralipid Infusion during Pregnancy as an Additive Treatment for Reducing Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome
AUTHORS:
Adel E. El-Gegawy, Hashem A. Lotfy, Shereef L. Elshwaikh
KEYWORDS:
Antiphospholipid Antibody, Intralipid, Recurrent Pregnancy Loss
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.11 No.4,
April
13,
2021
ABSTRACT: Aim: To evaluate the safety and efficacy of intralipid
infusion in addition to other lines of treatment in reduction of complications
caused by antiphospholipid antibody syndrome. Methods: This study was
held in the period from June 1, 2016, to December 1, 2019. This study was
conducted in the Department of Obstetrics and Gynecology, Tanta University on
patients attending the antenatal care clinic and also on patients attending the
researcher’s private clinics for antenatal care, 105 patients were enrolled after
application of strict inclusion and exclusion criteria. They were randomized into
2 groups. In group A (study group 1) the patients received in addition to the
conventional basic treatment of APS, intralipid 20% (Frezenius, Clayton, NC,
USA) in a dose of 4 ml diluted in 250 ml 0.9% regular saline IV and to be
repeated every 2 weeks. In group B (control group 2) the patients received the
conventional basic treatment of APS. The outcome measures were the incidence of
pregnancy complications of APS namely fetal loss, premature delivery, IUGR and
preeclampsia. Results: 49 patients were enrolled in the study group, and
48 patients were enrolled in the control group, after exclusion of the skipped
cases. The demographic data and the gestational age at the beginning of the
study show insignificant differences. There were insignificant differences as
regard the gestational age at which the pregnancy was terminated and fetal
birth weight in patients with positive ACL test, positive LA test and positive
B2 however the mean gestational age at which pregnancy was terminated was
higher in study group. Also, there was insignificant difference as regards no
of patients who complicated with abortion or who completed to full term. But
had significant decrease number of case who complicated with preeclampsia (8,
21 patients in study and control group respectively). Conclusion: Intralipid
infusion is a promising treatment option for control and prevention of problems
caused by antiphospholipid antibody syndrome.